Tevogen Bio Holdings Inc.
TVGN
$0.9364
$0.0323.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.13% | 79.87% | 427.74% | 232.07% | 152.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.39% | -4.53% | 505.72% | 365.70% | 266.09% |
| Operating Income | 26.39% | 4.53% | -505.72% | -365.70% | -266.09% |
| Income Before Tax | -425.62% | -91.58% | 77.30% | 87.35% | 90.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -425.62% | -91.58% | 77.30% | 87.35% | 90.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -425.62% | -91.58% | 77.30% | 87.35% | 90.66% |
| EBIT | 26.39% | 4.53% | -505.72% | -365.70% | -266.09% |
| EBITDA | 26.60% | 4.54% | -515.26% | -372.36% | -269.04% |
| EPS Basic | -53.84% | 20.93% | 86.17% | 79.53% | 83.60% |
| Normalized Basic EPS | 45.04% | 29.19% | -153.84% | -104.82% | -14.25% |
| EPS Diluted | 53.38% | 62.69% | 31.80% | 31.69% | 44.69% |
| Normalized Diluted EPS | 43.95% | 27.62% | -148.99% | -100.96% | -12.03% |
| Average Basic Shares Outstanding | 42.71% | 47.34% | 47.72% | 26.42% | 50.48% |
| Average Diluted Shares Outstanding | 41.08% | 45.51% | 49.04% | 27.74% | 52.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |